How Deadly Is AIDS: Life Expectancy and Survival

AIDS went from being a near-certain death sentence in the 1980s to a manageable chronic condition for most people who receive modern treatment. Without treatment, median survival after acquiring HIV ranges from about 8 to 13 years depending on age and geography. With sustained antiretroviral therapy and a strong immune response, life expectancy now falls only a few years short of the general population in high-income countries. That transformation is one of the most dramatic in the history of medicine, but the story is far from uniform across the globe, and the virus still kills when diagnosis comes late, treatment is interrupted, or access is limited.

Survival Without Treatment

Before effective antiretroviral drugs existed, an HIV diagnosis set a rough biological clock. A large evidence synthesis of seroconverter cohorts found that median survival without treatment varied sharply by age at infection: people infected between ages 15 and 24 survived a median of about 12.5 years, while those infected between 45 and 54 survived roughly 7 years. Older age at infection meant lower starting immune cell counts, faster immune decline, and higher mortality rates at every stage.¹

Geography mattered too. A joint estimation study across multiple regions found that a 20-year-old man infected with HIV could expect about 13 years of survival in Europe or North America, roughly 11.6 years in Africa, and only about 8 years in South and East Asia. Africa’s slightly shorter survival compared with high-income countries reflected a combination of co-infections, nutritional status, and limited healthcare access. The especially short survival in Asian cohorts was linked to faster immune decline, though researchers did not fully explain why.²

These numbers describe the natural history of untreated HIV. Once the immune system collapsed below a critical threshold and opportunistic infections set in, the diagnosis became AIDS, and survival from that point was measured in months rather than years. For context, the overall mortality rate in one large cohort was about 76 deaths per 100 person-years in 1995, the year before combination therapy became widely available.³

How Combination Therapy Changed Everything

The introduction of highly active antiretroviral therapy in the mid-1990s cut the death rate dramatically. In the same cohort that saw 76 deaths per 100 person-years in 1995, mortality dropped to about 33 deaths per 100 person-years by 1998-1999.³ That halving of deaths within just a few years was only the beginning. As drug regimens improved, became easier to take, and caused fewer side effects, life expectancy kept climbing.

Data from Switzerland illustrate the trajectory. Life expectancy at age 20 for a person with HIV rose from under 12 years during the era of single-drug treatment to nearly 55 years in the most recent era of combination therapy.⁴ That is a gain of more than four decades of expected life.

A collaborative analysis of cohort studies across Europe and North America found that for people with HIV on long-term treatment who had achieved high immune cell counts, life expectancy was only a few years lower than that of the general population, regardless of when they started therapy.⁵ “A few years lower” is not zero, and the gap is worth understanding, but it is a different universe from the pre-treatment era.

Why Early Diagnosis Matters So Much

The single biggest factor separating someone who lives a near-normal lifespan from someone who does not is how early they start treatment. A UK-based analysis showed that a 35-year-old man who began therapy with a very depleted immune system could expect to live to about 71, more than seven years less than the average British man. But if that same person responded well to treatment within the first year and rebuilt their immune cell counts, their expected lifespan rose to around 78 to 81 years, essentially matching the general population.⁶

Conversely, people who spent years on treatment without achieving viral suppression and whose immune counts stayed low faced dramatically worse outcomes. In the same analysis, a 35-year-old man who remained on therapy for five years but still had a depleted immune system and detectable virus could expect to live only to about 54. The difference between best-case and worst-case outcomes on treatment spanned more than 25 years of life.⁶

Late diagnosis remains a persistent problem worldwide. A systematic review and meta-analysis found that delayed HIV diagnosis is common and that late-diagnosed patients face substantially higher mortality rates.⁷ In parts of China, for instance, late presentation was very common among newly diagnosed patients, with older heterosexual men and people who inject drugs particularly likely to be diagnosed after their immune system had already been severely damaged.⁸

What People With HIV Die of Now

As treatment has pushed AIDS-related deaths down, the profile of what actually kills people with HIV has shifted. In Europe and North America, AIDS accounted for about half of deaths among people with HIV in the late 1990s. By 2016-2020, that proportion had dropped to roughly 16%. Over the same period, non-AIDS cancers rose from about 5% of deaths to 19%.⁹

Swiss data tell a similar story with even sharper numbers. AIDS-related deaths fell from about 19% of all deaths in people with HIV during 2005-2007 to under 4% by 2020-2022. Non-AIDS, non-hepatitis cancers went in the other direction, rising from about 15% to 31% of deaths. Cardiovascular disease held roughly steady at around 11%.¹⁰

This shift has practical implications. A person with well-controlled HIV today faces health risks that look more like those of the aging general population: heart disease, lung cancer, liver disease. The virus itself has been tamed, but the long-term toll of chronic low-grade inflammation has not been fully resolved.

The Lingering Problem of Chronic Inflammation

Even when antiretroviral therapy drives HIV to undetectable levels in the blood, the immune system does not fully return to normal. Multiple studies have found that markers of inflammation and immune activation remain elevated in people whose virus is completely suppressed. Research on “elite controllers,” people whose own immune systems suppress HIV without drugs, has confirmed that this persistent inflammation raises cardiovascular risk independently of the medications.¹¹

This residual inflammation helps explain why heart disease, stroke, and certain cancers remain elevated in people with HIV even when their virus is controlled and their immune cell counts have recovered. The inflammation appears to be driven partly by the virus’s continued presence in reservoirs the immune system cannot fully clear, and partly by the lasting damage done to the gut lining and lymph tissue early in infection.¹²

Tuberculosis and Other Co-Infections

Tuberculosis is the co-infection that costs the most lives. In 2023, about 24% of people who had both TB and HIV died, compared with 11% of TB patients without HIV.¹³ A meta-analysis focusing on children, adolescents, and young adults in sub-Saharan Africa with TB-HIV co-infection reported a pooled mortality of about 13% after co-treatment began. Advanced disease stage, poor adherence to antiretroviral drugs, missing preventive therapies, low hemoglobin, and very low immune cell counts were all strong predictors of death.¹⁴

A retrospective cohort study in Northwest Ethiopia found a mortality rate of about 16% among people with TB-HIV co-infection, with a median survival time of 42 months. Being male, having an extremely depleted immune system, and being bedridden at the start of treatment were all associated with much higher risk of death.¹⁵ TB-HIV overlap remains heaviest in sub-Saharan Africa and parts of South and Southeast Asia, where both diseases circulate widely and health systems are stretched thin.

The Global Access Gap

Almost everything said so far about near-normal life expectancy assumes uninterrupted access to modern drugs, regular lab monitoring, and healthcare for side effects and comorbidities. That assumption holds for most people with HIV in high-income countries. It does not hold across much of the world. Rates of new infection, illness, and death remain highest in low-income regions and lowest in high-income ones.¹⁶

The gap is driven by structural factors. In much of sub-Saharan Africa, people with HIV lack timely testing, consistent drug supply, and sustained follow-up care because primary healthcare infrastructure is thin. In wealthier countries, a combination of social insurance, medical assistance, and private insurance covers treatment costs. In low- and lower-middle-income countries, nearly half of HIV-related health spending relies on international donations, which can fluctuate year to year.¹⁷

Drug Resistance and Treatment Failure

When people start and stop treatment, take doses inconsistently, or receive suboptimal drug combinations, the virus can develop resistance. Modeling of sub-Saharan African populations estimated that where pre-treatment drug resistance reached 10% or higher, the consequences included about 16% more AIDS deaths per year, 8% lower viral suppression rates among people on treatment, and 9% higher rates of new infections.¹⁸

At the individual level, accumulating resistance across multiple drug classes is particularly dangerous. A cohort study found that people whose virus had developed resistance to three entire drug classes faced more than five times the risk of death compared to those without such broad resistance, after adjusting for other factors.¹⁹ Fortunately, newer drug classes have higher barriers to resistance, and the newest regimens make it harder for the virus to escape. But resistance surveillance matters, especially in regions rolling out treatment at scale.

Mental Health, Sex Differences, and Aging

Survival with HIV is not purely a virological question. Mental health disorders shorten the lives of people with HIV by measurable amounts. A study across South Africa, Canada, and the United States found that mental health conditions were associated with roughly three to five lost years of life among people with HIV, with psychotic disorders and substance use disorders taking a heavier toll than depression or anxiety alone.²⁰ Mental health problems interfere with adherence, and missed doses let the virus rebound and the immune system weaken.

Biological sex also shapes the HIV experience. Women in lower-income countries are more likely than men to access testing and treatment and achieve viral suppression. But the same enhanced immune responses that help women fight infections appear to raise their risk of cardiovascular and cerebrovascular disease over the long term, and emerging data suggest sex differences in how the virus hides in reservoirs.²¹ In high-income settings, women with HIV are more likely to face barriers related to caregiving responsibilities, intimate partner violence, and reproductive health management that indirectly affect treatment continuity.²²

As the first generation of people who survived thanks to combination therapy enters their 60s and 70s, a new challenge is emerging: accelerated aging. Frailty, a syndrome of declining physical and functional reserve, has a prevalence of roughly 5-30% in people aging with HIV and appears to set in up to two decades earlier than in the general population.²³ This early frailty is thought to reflect the cumulative effects of chronic inflammation, long-term drug exposure, and the virus’s early damage to the immune system.

Children Growing Up With HIV

Thanks to antiretroviral therapy, most children born with HIV now survive into adulthood.²⁴ That success creates a new clinical challenge: transitioning young people from pediatric to adult HIV care. A systematic review found that more than 70% of adolescents with HIV remained in care one to two years after transitioning, though immune markers and viral control sometimes wobbled during the adjustment period.²⁵ Having been on antiretroviral therapy for more than two years and transitioning at age 18 or older were both associated with better outcomes after the handoff.²⁶

Long-Acting Drugs and the Future of Adherence

Daily pill-taking has been the standard since the 1990s, and missing doses remains one of the main reasons treatment fails. Long-acting injectable antiretrovirals, given once a month or once every two months, offer a way around this. Phase 3 trials showed that injectable cabotegravir and rilpivirine kept the virus suppressed for at least 124 weeks, performing as well as daily pills.²⁷

Real-world demonstration projects have confirmed these results beyond clinical trial conditions. In one diverse cohort, all participants who entered with an undetectable viral load maintained suppression on long-acting injections, and among those who started with a detectable viral load, about 97% achieved suppression. The virologic failure rate was around 1.5%, comparable to what was seen in the original clinical trials.²⁸ A separate study found that at 24 weeks, 97% of people who started the injections with detectable virus achieved suppression, a figure that held at 98% through 48 weeks.²⁹

For people who struggle with daily pills because of housing instability, stigma, mental health challenges, or simply the psychological burden of a daily reminder, bimonthly injections change the equation. This is not a marginal improvement. Treatment that works but is not taken is, for practical purposes, treatment that does not work.

Viral Suppression and Transmission

The benefits of viral suppression extend beyond the person taking the drugs. Three landmark studies (Opposites Attract, PARTNER, and PARTNER2) tracked thousands of sexual encounters between couples where one partner had HIV and the other did not. When the HIV-positive partner had a viral load below 200 copies per milliliter, no linked transmissions occurred.³⁰ This finding, summarized as “undetectable equals untransmittable,” has reshaped public health messaging and reduced stigma for people living with HIV who maintain treatment.

Cure Research and Rare Remission Cases

A functional cure remains elusive for most, but a handful of cases have shown it is biologically possible. The first was a man who received a bone marrow transplant from a donor carrying two copies of a rare genetic mutation that blocks HIV’s main entry point into cells. The transplant replaced his immune system with one that the virus could not easily infect. This approach stimulated a broader search for strategies to eradicate the virus or induce long-term remission without ongoing drugs.³¹

More recent cases have confirmed the principle. In one patient who received a transplant from a sibling donor carrying the same protective mutation, researchers found no intact viral DNA in more than 3 million immune cells from the blood four years after the transplant. Gut tissue biopsies also came up clean for intact virus. Testing more than 65 million immune cells failed to recover any virus capable of replicating, suggesting the reservoir had been eliminated.³²

Bone marrow transplants are not a scalable cure. They carry serious risks, including graft-versus-host disease and infection, and are only performed when a person also has a blood cancer that requires one. In the largest reported series of such transplants in people with HIV, overall survival was about 82% at six months and 57% at one year, numbers comparable to transplant outcomes in people without HIV but still carrying substantial mortality.³³ The value of these cases lies in proving the concept: the virus can be cleared from the body. The challenge is doing it safely enough to offer to the tens of millions of people currently managing HIV with daily or monthly treatment.